BIVV001 (rFVIIIFc-VWF-XTEN)
Hemophilia A
Phase 3Active
Key Facts
About Swedish Orphan Biovitrum
Sobi is a premier rare disease company with a mission to pioneer and deliver life-changing therapies for underserved patient populations. The company has established a strong commercial foundation with marketed products in hematology and immunology, complemented by a diversified pipeline of biologics and small molecules. Its strategy hinges on expanding global access, advancing high-potential clinical programs, and maintaining operational excellence to drive sustainable growth and leadership in the rare disease space.
View full company profileTherapeutic Areas
Other Hemophilia A Drugs
| Drug | Company | Phase |
|---|---|---|
| GS1191 | Gritgen Therapeutics | Phase 1 |
| FVIII-GMAC | CellGenTech | Preclinical |
| Coagulation Factor VIII | Shanghai RAAS Blood Products | Marketed |
| Human Coagulation Factor VIII | Hualan Biological Engineering | Marketed |
| Giroctocogene fitelparvovec (SB-525) | Sangamo Therapeutics | Phase 3 |